Preclinical Safety Testing of Biotechnology-Derived Pharmaceuticals: Understanding the Issues and Addressing the Challenges

By Brennan Frank R.   Shaw Leigh   Wing Mark G.   Robinson Christine  

Molecular Biotechnology, Vol. 27, Iss. 1, 2004-05 ,pp. : 59-74

Humana Press, Inc

Access to resources Recommend Favorite

Preclinical and clinical pharmacology of antisense oligonucleotides

By Marcusson E.   Yacyshyn B.   Shanahan W.   Dean N.  

Molecular Biotechnology, Vol. 12, Iss. 1, 1999-08 ,pp. : 1-11

Humana Press, Inc

Access to resources Recommend Favorite

How meaningful are risk determinations in the absence of a complete dataset? Making the case for publishing standardized test guideline and ‘no effect’ studies for evaluating the safety of nanoparticulates versus spurious ‘high effect’ results from single investigative studies

By  

Science and Technology of Advanced Materials, Vol. 16, Iss. 3, 2015-06 ,pp. : 200-204

IOP Publishing

Access to resources Recommend Favorite

STM studies of 1-D noble metal growth on silicon

By Baski A.A.   Jones K.M.   Saoud K.M.  

Ultramicroscopy, Vol. 86, Iss. 1, 2001-01 ,pp. : 23-30

Elsevier

Access to resources Recommend Favorite

SARS-CoV Nucleocapsid Protein Induced Apoptosis of COS-1 Mediated by the Mitochondrial Pathway

By Zhang Lu   Wei Lai   Jiang Dong   Wang Jianghua   Cong Xu   Fei Ran  

Artificial Cells, Blood Substitutes, and Biotechnology (formerly known as Artif, Vol. 35, Iss. 2, 2007-03 ,pp. : 237-253

Informa Healthcare

Access to resources Recommend Favorite